We Offer Worldwide Shipping
Login Wishlist

Fmoc-O-(benzylphospho)-L-threonine

$64

  • Brand : BIOFRON

  • Catalogue Number : BN-O1010

  • Specification : 98%(HPLC)

  • CAS number : 175291-56-2

  • Formula : C26H26NO8P

  • Molecular Weight : 511.46

  • PUBCHEM ID : 2761490

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1010

Analysis Method

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

511.46

Appearance

Powder

Botanical Source

Structure Type

Category

SMILES

CC(C(C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13)OP(=O)(O)OCC4=CC=CC=C4

Synonyms

L-Threonine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-O-[hydroxy(phenylmethoxy)phosphinyl]-/L-PHOSPHOTHREONINE/Fl332-1/(2S,3R)-3-{[(Benzyloxy)(hydroxy)phosphoryl]oxy}-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}butanoic acid/FMOC-O-BENZYL-L-PHOSPHOTHREONINE/O-[(Benzyloxy)(hydroxy)phosphoryl]-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-threonine/Fmoc-Thr(HPO3Bzl)-OH/Fmoc-Thr(PO3BzlH)-OH/Fmoc-O-Bn-phospho-L-threonine

IUPAC Name

Density

1.4±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

Boiling Point

Melting Point

InChl

InChl Key

HOFDVXHILSPFNS-BXKMTCNYSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:175291-56-2) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

30008270

Abstract

Background
Antiretroviral therapy (ART) has become the standard of care for patients with HIV infection in South Africa and has led to the reduction in AIDS related morbidity and mortality. In developing countries, the nucleosides reverse transcriptase inhibitors (NRTIs) class are widely used because of their low production costs. However patients treated with NRTIs develop varying degree of toxicity after long-term therapy. For this study patients are administered with a triple therapy of two NRTIs and one non-nucleoside reverse transcriptase inhibitor (NNRTI).

Method
In this study the progression of HIV in vivo is divided into some viral load states and a continuous time-homogeneous model is fitted to assess the effects of covariates namely gender, age, CD4 baseline, viral load baseline, lactic acidosis, peripheral neuropathy, non-adherence and resistance to treatment on transition intensities between the states. Effects of different drug combinations on transition intensities are also assessed.

Results
The results show no gender differences on transition intensities. The likelihood ratio test shows that the continuous time Markov model for the effects of the covariates including combination give a significantly better fit to the observed data. From almost all states, rates of viral suppression were higher than rates of viral rebound except for patients in state 2 (viral load between 50 and 10,000 copies/mL) where rates of viral rebound to state 3 (viral load between 10,000 and 100,000 copies/mL) were higher than rates of viral suppression to undetectable levels. For this transition, confidence intervals were very small. This was quite notable for patients who were administered with AZT-3TC-LPV/r and FTC-TDF-EFV. Although patients on d4T-3TC-EFV also had higher rates of viral rebound from state 2 than suppression, the difference was not significant.

Conclusion
From these findings, we can conclude that administering of any HIV drug regimen is better when based on the viral load level of an HIV+ patient. Before initiation of treatment, patients should be well equipped on how antiretroviral drugs operate including possibilities of toxicity in order to reduce chances of non-adherence to treatment. There should also be a good relationship between patient and health-care-giver to ensure proper adherence to treatment. Uptake of therapy by young patients should be closely monitored by adopting pill counting every time they come for review.

KEYWORDS

HIV progression, Viral load, Lactic acidosis, Peripheral neuropathy, Non-adherence, Triple therapy

Title

Determinants of viral load rebound on HIV/AIDS patients receiving antiretroviral therapy: results from South Africa

Author

Claris Shokocorresponding author and Delson Chikobvu

Publish date

2018;


Description :

Empty ...